SCHEMBL1017404

SCHEMBL1017404

COC(=O)c1ccc(Cl)cc1CBr

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.58
NR4A2 P43354 2/20 0.48
ALDH1A1 P00352 4/20 0.44
LMNA P02545 2/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
PDK2 Q15119 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28068823 0.87 ABL1 (0.55) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL29752442 0.87 ABL1 (0.54) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL942693 0.87 ABL1 (0.54) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL10487662 0.86 ABL1 (0.62) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL1774240 0.85 MAPT (0.49) ABL1ALDH1A1LMNAMAPTNPC1
SCHEMBL16960452 0.85 ABL1 (0.60) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL5250038 0.84 CYP4F2 (0.56) RXFP1SMN1; SMN2CA12CA1CA2
SCHEMBL17844846 0.83 ABL1 (0.58) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL11321881 0.83 ABL1 (0.58) ABL1NR4A2ALDH1A1LMNASLC6A4
SCHEMBL9384521 0.82 ABL1 (0.57) ABL1NR4A2ALDH1A1LMNASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103058913-A Method for synthesizing 5-isoindolone chloride CHEMFUTURE PHARMATECH JIANGSU CO LTD 2013-04-24 CN claimed
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US disclosed
EP-4734979-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-05-06 EP disclosed
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 EP disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 US disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US disclosed
EP-3706747-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-09-03 EP disclosed
EP-4598908-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS Pfizer Inc. (US) 2025-08-13 EP disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 US disclosed
EP-1697304-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-09-06 EP disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed
WO-2005054176-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-16 WO disclosed
EP-1519925-A1 OXAZOLE DERIVATIVES AND THEIR USE AS INSULIN SENSITIZERS F. HOFFMANN-LA ROCHE AG (CH) 2005-04-06 EP disclosed
US-6747049-B2 NON-INSULIN DEPENDENT DIABETES MELLITUS. HOFFMANN-LA ROCHE INC. 2004-06-08 US disclosed
WO-2004005266-A1 OXAZOLE DERIVATIVES AND THEIR USE AS INSULIN SENSITIZERS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-15 WO disclosed
US-20040006116-A1 Oxazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-01-08 US disclosed
EP-0759911-A1 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES RHONE POULENC AGRICULTURE LTD. (GB) 1997-03-05 EP disclosed
WO-1995031446-A1 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES RHONE POULENC AGRICULTURE LTD. (GB) 1995-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006116-A1 Oxazole derivatives GPR119, IRS1, INSR ABL1 1568/4885NR4A2 352/4885ALDH1A1 197/4885
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS ABL1 2874/4885NR4A2 1505/4885ALDH1A1 4610/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS ABL1 2303/4885NR4A2 736/4885ALDH1A1 4143/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 ABL1 3384/4885NR4A2 139/4885ALDH1A1 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.